USP15 REGULATES NEUROINFLAMMATION AND DRIVES PATHOGENESIS IN SYNUCLEINOPATHIES

Parkinson's disease is a condition that slowly steals away a person's ability to move, causing tremors, stiffness, and a loss of balance. For decades, scientists have focused on the brain cells that die during this process, specifically the neurons that produce a chemical called dopamine. However, recent research has shifted attention toward the brain's immune system. Just as the body has white blood cells to fight infection, the brain has its own specialized immune cells called microglia and astrocytes. These cells normally act as caretakers, cleaning up debris and protecting neurons. But in Parkinson's disease, they can become overactive, releasing a flood of inflammatory signals that damage healthy neurons instead of protecting them. This state of constant, low-level inflammation, known as neuroinflammation, is now understood to be a major driver of the disease, accelerating the loss of brain cells long before movement problems become obvious.

A new study has identified a specific protein that acts as a master switch for this harmful inflammation. The researchers found that a molecule called USP15 is essential for turning on the brain's inflammatory response. When this protein is present, immune cells in the brain react strongly to trouble signals, releasing chemicals that can damage surrounding tissue. When the protein is removed or disabled, that inflammatory reaction is significantly dampened. In experiments using mice that model Parkinson's disease, removing USP15 slowed the progression of the disease, reduced the accumulation of toxic protein clumps in the brain, and allowed the animals to live longer. The study suggests that by targeting this single protein, it might be possible to calm the brain's immune system and protect neurons from the damage that leads to Parkinson's.

The research team began by testing how USP15 functions in the brain's immune cells. They created mice that were genetically engineered to lack the USP15 protein in either their microglia or their astrocytes. To see how these cells reacted to stress, they infected the mice with a parasite that causes severe brain inflammation, similar to a dangerous form of malaria. In normal mice, this infection triggers a massive immune response that is often fatal. However, the mice without USP15 in their brain immune cells survived the infection at much higher rates. When the researchers looked inside the brains of these surviving mice, they found that the usual flood of inflammatory genes was missing. The cells simply did not turn on the same aggressive defense mechanisms that usually cause so much damage. This proved that USP15 is a critical regulator of how these brain cells respond to danger.

Next, the team wanted to see if this same mechanism played a role in Parkinson's disease specifically. They used a mouse model that carries a human genetic mutation known to cause early-onset Parkinson's. These mice naturally develop clumps of a protein called alpha-synuclein, which is the hallmark of the disease in humans. The researchers injected these mice with pre-formed clumps of the protein to speed up the disease process. They compared mice that had normal levels of USP15 with those that had a broken version of the gene. The mice with the broken gene developed symptoms much later than the normal mice. They lost less weight, maintained their motor skills for a longer time, and lived significantly longer. When the researchers examined the brains of these mice, they found far fewer toxic protein clumps in the areas responsible for movement. The absence of USP15 had effectively slowed down the spread of the disease.

To understand exactly how this protection worked, the scientists analyzed the genetic activity in the brains of the mice. They discovered that the mice with the broken USP15 gene failed to activate a specific set of genes known as interferon-stimulated genes. These genes are part of the body's antiviral defense system, but in the context of Parkinson's, they seem to drive the harmful inflammation that kills neurons. In normal mice, the presence of the toxic protein clumps triggered a strong surge in these genes. In the mice without functional USP15, this surge was blunted. The immune cells remained calmer, and the brain environment was less hostile to the neurons. This finding was confirmed in human cells as well. The researchers took human stem cells and turned them into microglia and astrocytes in a lab dish. When they disabled the USP15 gene in these human cells and then exposed them to a virus-like trigger, the cells again failed to mount the usual intense inflammatory response. This showed that the role of USP15 is conserved across species and is fundamental to how human brain immune cells behave.

The study also looked at whether this protein is relevant to actual human patients. The researchers examined genetic data from large groups of people with Parkinson's disease. They found that a specific region of human DNA containing the USP15 gene is associated with an increased risk of developing the disease. People who carry a certain version of this gene tend to have higher levels of USP15 in their immune cells. Furthermore, previous studies have shown that the level of USP15 protein in the blood is higher in people with Parkinson's compared to those without. This genetic link, combined with the experimental results, suggests that high levels of this protein may be a risk factor for the disease. The researchers also noted that USP15 is often found in the same brain cells as other proteins known to be involved in Parkinson's, such as LRRK2 and alpha-synuclein, placing it right at the center of the disease's molecular machinery.

The implications of these findings are significant for how scientists might approach treating Parkinson's in the future. For a long time, the focus has been on replacing lost dopamine or clearing out toxic protein clumps. This study suggests a different strategy: calming the brain's immune system before it causes irreversible damage. By finding a way to reduce the activity of USP15, it might be possible to stop the inflammatory cycle that drives the disease forward. The researchers emphasize that while their work in mice and human cells is promising, it is still early. They have shown that removing this protein protects the brain, but they have not yet tested drugs that could safely lower its activity in people. However, the identification of USP15 as a key driver of neuroinflammation provides a clear new target for drug developers. If a medication can be designed to block this specific protein, it could potentially slow the progression of Parkinson's disease, preserving movement and quality of life for patients for much longer than is currently possible.